secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2026-08-05T20:13:22+00:00
Accession:  0001434647-26-000067
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Q2 2026 net revenue $39.7M, up 53% YoY; MIPLYFFA drives growth
--------------------------------------------------------------------

- Net revenue $39.7M, including $30.2M from MIPLYFFA; up from $25.9M in Q2 2025.
- Net income $8.8M ($0.14 per share); adjusted net income $15.2M ($0.25 per share).
- Cash, cash equivalents and investments $260.2M as of June 30, 2026.
- 14 MIPLYFFA prescription enrollment forms in Q2; total 184 since launch; 69% covered lives.
- 66 patients enrolled in Phase 3 DiSCOVER trial for celiprolol; EU MAA re-examination requested.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143464726000067/0001434647-26-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143464726000067/zvra-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001434647-26-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer